Recent studies have identified HER2-low breast cancer as a distinct subgroup within the HER2-negative category, defined by immunohistochemistry (IHC) scores of 1+ or 2+ without HER2 gene amplification by in situ hybridization (ISH) [4]. This evidence concerns the gene ERBB2 and breast cancer.